Skip to content

Insider · CIK 0001573429

Matthew Pauls

ceoofficerdirector

Files at SVRA (Savara Inc), PTHS (Channel Therapeutics Corp). First filing Dec 16, 2024, latest Oct 6, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $197k sold

Where the trades landed

Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.

PTHS: Channel Therapeutics Corp

PTHSOct 9, 2026 · close 20.50

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

SVRA: Savara Inc

SVRAOct 9, 2026 · close 4.92

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
10Weak
PTHSsell 310b5-1
Channel Therapeutics Corp
$17k
786 shares
-5%-
52Moderate
SVRAsell 3
Savara Inc
$181k
54,702 shares
-3%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 2, 2026PTHS
Channel Therapeutics Corp
SOpen-market sale
Common Stock10b5-1
-786$21.00$17k13,5786 d ago
Dec 12, 2024SVRA
Savara Inc
AGrant or award
Common Stock
+400,000$0.00$01,683,674Dec 16, 2024
Dec 13, 2024SVRA
Savara Inc
FTax withholding
Common Stock
-92,593$3.21$297k1,591,081Dec 16, 2024
Dec 16, 2024SVRA
Savara Inc
SOpen-market sale
Common Stock
-54,702$3.31$181k1,536,379Dec 16, 2024
Dec 12, 2024SVRA
Savara Inc
AGrant or award
Stock Option (Right to Buy)derivative
+900,000$0.00$0900,000Dec 16, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Matthew Pauls: insider trades and track record | InsiderTell